PDCD1 and hepatocellular carcinoma: Targeting the immune checkpoint programmed cell death protein-1 (PD-1), alone or in combination with CTLA-cytotoxic T-cell antigen 4 (CTLA-4) blockade, in advanced HCC demonstrated a survival benefit [12,13,14,15].